

iPS cells and personalized mediciné

Ass. Prof. Darko Bosnakovski; Ph.D

Faculty of Medical Sciences
University "Goce Delcev" Stip
R. Macedonia

darko.bosnakovski@ugd.edu.mk

Personalized medicine

- I want to know the mechanism of the diseases ???
- Probably you will need a suitable model ???
- I need a specific therapy (ASAP) ???


 We will need a lot of money to achieve all of that !!!



@ beboy * www.ClipartOf.com/29638

Facioscapulohumeral Muscular Dystrophy (FSHD)


- FSHD is an autosomal dominant inherited disorder
- Third most common inherited neuromuscular condition (1:8000)
- Disease onset is unusual before the age of 10
- Muscles on the face are first affected, then the symptoms are progressive
- There is no specific treatment.






Deletion on chromosome 4 is an initial factor for FSHD

Is DUX4 a key player in the molecular mechanism?




Predictions !!! 4q35A locus is open and transcriptionally active in FSHD




DUX4 and **FSHD**


FSHD cells express DUX4



DUX4 induces cell death


Control + DUX4





MyHC/DAPI

DUX4 affects myogenesis
Control DUX4



<u>Bosnakovsk</u>i et al.; PlosOne 2009 <u>Bosnakovsk</u>i et al.; EMBO J 2008 <u>Bosnakovsk</u>i et al.; Exp Neurol 2008